Green Valley Announces NMPA Approval Of Oligomannate For Mild To Moderate Alzheimer’s Disease
- Sunday, November 3, 2019, 7:14
- PR Newswire
- Add a comment
Oligomannate , A New Oral Treatment For Mild To Moderate Alzheimer’s Disease The Only Approved Novel AD Treatment Globally Since 2003 SHANGHAI, Nov. 2, 2019 /PRNewswire/ — Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China’s National Medical Products…
About the Author
admin has written 20652 stories on this site.